VEGF NEUTRALISING PRODRUGS FOR THE TREATMENT OF OCULAR CONDITIONS Russian patent published in 2018 - IPC A61K39/395 A61K47/50 A61P27/02 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, specifically, to ophthalmology and oncology, and can be used to treat diseases associated with ocular neovascularization. To this end, a pharmaceutical composition for intraocular administration is administered by intraocular injection. Said composition comprises one or more pharmaceutically acceptable excipients and a carrier-linked VEGF neutralising prodrug. Carrier-linked prodrug comprises a covalently bound VEGF-neutralising biologically active fragment, a fragment of a reversible prodrug linker and a carrier group that is a biodegradable hydrogel selected from the group consisting of PEG-based hydrogels and hyaluronic acid. VEGF-neutralising biologically active fragment is reversibly linked to the carrier via a fragment of the reversible prodrug linker.

EFFECT: invention provides an increase in the vitreal half-life of the VEGF neutralising prodrug as compared to the non-linked VEGF neutralising biologically active fragment.

19 cl, 3 tbl, 46 ex